Physicians Must Become Advocates to Play a Role in Community Oncology’s Future
September 25th 2023Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.
Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC
September 22nd 2023Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer
Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice
September 20th 2023As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.
Novel PROTAC May Usher in New Class of Drugs for ESR1+, ER+/HER2– Breast Cancer
September 18th 2023The development of novel next-generation hormonal agents is poised to change the landscape for patients with estrogen receptor-positive, HER2-negative breast cancer, offering additional oral solutions to lessen the burden of the invasive delivery of the standard of care and provide agents that are active against acquired variants.
Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal
September 6th 2023The well-publicized severe shortage of vitally important generic antineoplastic agents has highlighted a serious misalignment in the existing market-based and regulatory environment that permitted such an extraordinary situation to develop without meaningful resolution.